This further strengthens a SMAD4 loss-of-function driven increased sensitivity towards MEK-inhibitors that may be of use as a predictive biomarker for clinically successful MEK-inhibitor therapy in CRC. Here, MAP2K7 is linked to colorectal carcinoma.